Vertiserc

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vertiserc

Quick Facts

Property Description
Active Ingredient Betahistine
Form Tablet; Oral Solution
Pharmacological Class Antivertigo Agent; Histamine Analogue
Common Purpose Stabilizing balance; relieving vertigo and dizziness
Origin Synthetic

What is Vertiserc, and What Class Does it Belong To?

Vertiserc is a proprietary prescription-only medication that contains the active ingredient Betahistine and is primarily classified as an Antivertigo Agent. The drug is intended for oral administration and is distinguished by its core component, Betahistine, which is a synthetic structural analogue of histamine. The Anatomical Therapeutic Chemical (ATC) classification system designates Betahistine under the code N07CA01, which groups preparations specifically used for treating vertigo. This specialized pharmacological role is clinically recognized for targeting symptoms associated with inner ear dysfunction, setting it apart from general anti-nausea medications.

Understanding the Composition and Purpose of Betahistine

The medicinal substance in Vertiserc is Betahistine, most commonly prepared as a single active component in stable salt forms, such as Betahistine dihydrochloride or Betahistine mesilate. While generally provided as an oral tablet, an oral solution is also formulated in certain markets. Betahistine is primarily used for the symptomatic treatment of vestibular vertigo. This emphasizes that its principal role is to help reduce the intensity of spinning sensations in adult patients. The drug's overall purpose is to help relieve the distressing sensations of vertigo and associated severe dizziness by promoting the process of central vestibular compensation and improving microcirculation within the inner ear.

Regulatory References

  1. WHO

What side effects are possible with Vertiserc?

Possible Side Effects and Safety Information

Official regulatory documentation structures the safety profile of Betahistine (Vertiserc) by classifying adverse reactions according to frequency and affected organ system. This information is derived from clinical studies and post-marketing surveillance reports.


Frequency-Classified Adverse Reactions

Adverse reactions that are Common (occurring in up to 1 in 100 users) include headache, nausea, and dyspepsia (indigestion). Reactions reported from post-marketing surveillance, for which frequency is Not Known, include hypersensitivity reactions (such as anaphylaxis) and various cutaneous and subcutaneous reactions, including rash, itching, and angioneurotic edema (swelling).


Safety Constraints and Special Populations

Regulatory labels indicate specific safety constraints for use. The medicine is formally contraindicated in individuals with a specific type of adrenal gland tumor known as phaeochromocytoma. Caution and careful monitoring are specifically noted for patients with pre-existing conditions, including a history of peptic ulceration or bronchial asthma.

Use in the pediatric population (individuals under 18 years) is not recommended due to a lack of sufficient data on safety and efficacy in this age group. Based on post-marketing experience, no formal dose adjustment is indicated for older adults or for patients with renal or hepatic impairment. Official documentation also notes that the medicine is considered unlikely to affect the ability to drive or operate machinery, specifically in the context of treating Meniere’s syndrome.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Betahistine (Vertiserc) overdose defines a range of documented manifestations and specific required emergency actions.

Documented Manifestations and Severity

Less severe clinical presentations following overdose may include common gastrointestinal disturbances such as nausea, vomiting, dyspepsia, abdominal pain, and dry mouth. Accompanying neurological signs often reported in labeling are somnolence (drowsiness) and ataxia (impaired coordination).

The official labeling cautions that more serious and potentially life-threatening outcomes have been reported, particularly at very high doses or when the overdose occurs in combination with other substances. These severe complications include convulsions (seizures), as well as documented cardiac and pulmonary complications.

Emergency Action and Management

Urgent medical attention is required for any suspected overdose exposure. Regulatory guidance mandates seeking immediate help by contacting a healthcare professional, a hospital emergency department, or a regional Poison Control Centre. This action is required immediately, even if the individual is not exhibiting signs of distress.

In terms of procedural management, treatment is symptomatic and supportive. While gastric lavage may be considered soon after ingestion, the official documents state that no specific antidote for Betahistine is currently known. This lack of a specific antidote makes prompt medical supervision essential.

Therapeutic Uses of Vertiserc

Main Uses and Therapeutic Intent

Vertiserc, which contains the active ingredient betahistine dihydrochloride, is primarily prescribed for the management of Ménière's disease and the symptomatic relief of various forms of vestibular vertigo. The medication is classified as an antivertigo agent and is intended to address the underlying physiological disturbances in the inner ear that lead to balance and hearing issues.

Ménière's Disease

The most common application of Vertiserc is the treatment of Ménière's disease, a chronic disorder of the inner ear. The treatment objective is to reduce the frequency and severity of the symptom cluster associated with this condition, which typically includes:

  • Vertigo: Recurrent episodes of a spinning sensation or dizziness, often accompanied by nausea or vomiting.
  • Tinnitus: The perception of ringing, buzzing, or other noises in the ear without an external sound source.
  • Hearing Loss: Progressive or fluctuating difficulty in hearing, often localized to one ear.

Vestibular Vertigo

Beyond Ménière's disease, Vertiserc is used to treat vestibular vertigo. This refers to dizziness caused by dysfunction within the vestibular system—the part of the inner ear and brain that controls balance. It helps mitigate the false sensation of movement or rotation, improving a patient's stability and ability to perform daily activities.

Expected Benefits and Mechanism Overview

The therapeutic goal of Vertiserc is to improve the microcirculation within the inner ear. By acting on histamine receptors, the medication is thought to reduce endolymphatic pressure. The endolymph is the fluid contained within the inner ear; when pressure levels are abnormal, it can disrupt both balance and auditory signals.

Key benefits of successful treatment include:

  • Reduction in Vertigo Frequency: Decreasing the number of sudden dizzy spells.
  • Symptom Mitigation: Lowering the intensity of dizziness and associated physical discomfort.
  • Auditory Stabilization: Helping to manage the progression of hearing impairment and the persistence of tinnitus in patients with inner ear pressure imbalances.

Regulatory References

  1. Summary of Product Characteristics on Betahistine

Eligibility and Restrictions for Use

Who Can and Cannot Use Vertiserc?

The population eligibility for using Vertiserc (Betahistine) is strictly defined by regulatory labeling, outlining specific groups who are allowed, restricted, or absolutely prohibited from use.

Absolute Contraindications

Vertiserc is formally contraindicated (must not be used) in patients with phaeochromocytoma (a tumor of the adrenal gland) and in individuals with a known hypersensitivity to Betahistine or any of the product's components. In some regulatory texts, active peptic ulceration is also listed as a contraindication.

Age and Developmental Status

  • Adults (18 years and over): This is the approved age group for which the medicine is indicated.
  • Children and Adolescents (Under 18): Use is not recommended due to insufficient regulatory data on safety and efficacy in this age group.
  • Pregnancy and Breastfeeding: Use during pregnancy is not recommended unless the prescribing physician determines it is clearly necessary. It is not known if the active substance is excreted in human milk, and use requires caution.

Conditions Requiring Caution

Careful monitoring is required for patients with bronchial asthma and those with a history of peptic ulceration or severe hypotension (very low blood pressure). However, for the elderly population and patients with renal or hepatic impairment, no dose adjustment appears necessary based on post-marketing experience, though clinical data may be limited.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products: Official Regulatory Information for Vertiserc

Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Histamine H1 antagonists (antihistamines), Monoamine Oxidase Inhibitors (MAOIs).
Specific interacting medicines (if explicitly listed) Selegiline (as an example of an MAO-B selective inhibitor).
Mechanistic basis of interactions (only if stated in label) Inhibition of Betahistine metabolism by MAOIs; Pharmacodynamic antagonism with H1 antagonists.
Timing-based interaction rules (if applicable) No mandatory timing separation rules are specified for any medicinal products. Food only slows the rate of absorption.
Population-specific interaction notes (if applicable) No population-specific interaction cautions are explicitly documented in the interaction section.

Interaction Classifications (High-Level)

Category Official Regulatory Statement
Interaction severity classification (as defined in official documents) Caution recommended (for MAOIs); Mutual attenuation of effect (for Antihistamines); No clinically significant in-vivo interaction expected (for CYP enzymes).
Regulatory basis (EMA / FDA / etc.) Information derived from the Summary of Product Characteristics (SmPC) and equivalent government regulatory documents.
Interaction-context constraints (as defined in official documents) Concomitant use with H1 antagonists may affect the efficacy of one of the medicinal products.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with Antihistamines ( H1 antagonists) may lead to a mutual attenuation of effect.
  • Monoamine Oxidase Inhibitors (MAOIs), including MAO-B selective inhibitors, may inhibit the metabolism of the medicine, which may increase the exposure of betahistine. Caution is recommended for this combination.
  • Food intake only slows down the rate of absorption of the medicine, while the total absorption remains similar.
  • No clinically significant Cytochrome P450 (CYP) enzyme interactions are expected based on in vitro data.

Connection to the overall interaction profile (2–4 sentences): The regulatory documents define the product's interaction structure primarily through two domains: potential pharmacodynamic antagonism with other histamine-modulating agents and a pharmacokinetic constraint related to its metabolism by MAO enzymes. The profile explicitly states that no medicinal products are formally prohibited for co-administration in the interaction section, and it details a common administration constraint where food only affects the absorption rate, not the total exposure.

Mechanism of Action

Histamine H3 Receptor Antagonism for Central Balance

Vertiserc (betahistine) primarily exerts its central action by functioning as an antagonist at the presynaptic histamine H3 receptor ( H3 R), particularly within the brainstem's vestibular nuclei. This H3 R blockade removes an inhibitory autoreceptor mechanism, leading to an increased release and turnover of endogenous histamine. This elevated histaminergic activity modulates the balance signaling pathways to promote the central reorganization of vestibular input .


Dual Action on Inner Ear Microcirculation

Simultaneously, Vertiserc acts as a partial agonist on the peripheral histamine H1 receptor ( H1 R) found on the blood vessels supplying the inner ear (vestibule and cochlea). This engagement of H1 R triggers a local vasodilatory response, which enhances microcirculation and is associated with alterations in endolymphatic pressure within the labyrinthine structures.


System Integration and Asymmetry Modulation

These combined central and peripheral effects produce a dual modulation of vestibular signaling and circulation. This pharmacological action supports a reduction in firing asymmetry between the signals originating from the vestibular organs, resulting in the adjustment of vestibular signal integration within the central nervous system.

Dosage and Administration Information

How Vertiserc is Used: Official Administration Guidelines

Vertiserc, which contains Betahistine, is intended for oral administration. The medicine is primarily available as tablets in strengths such as 8 mg, 16 mg, and 24 mg. The total daily dose for adults typically falls within the range of 24 mg to 48 mg, with a maximum daily dose that should not generally exceed 48 mg.


Dosing Schedule and Context

The full daily dose must be administered in divided doses throughout the day, usually taken as two or three separate doses (BID or TID). To facilitate proper delivery and manage potential mild digestive discomfort, the tablets should be taken preferably with meals or immediately after consuming food. If a dose is missed, the user should skip the forgotten dose and take the next dose at the regularly scheduled time; a double dose should not be taken to make up for the missed one.


Administration Rules for Specific Populations

Treatment with Vertiserc is often characterized as long-term, continuing for several months as the dose is individually adjusted based on the response observed over time. For older adults, no routine dose adjustment is typically considered necessary. However, the use of Betahistine is not recommended for patients under 18 years of age due to a lack of sufficient data regarding safety and efficacy in the pediatric population. Similarly, dose adjustments are generally not considered necessary for patients with known renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence Overview for Vertiserc (Betahistine)


Evidence for use in Ménière's Disease

Research has been conducted examining Vertiserc in adults with Ménière's disease, a condition characterized by fluctuating or episodic manifestations, including vertigo, tinnitus, and hearing changes. These investigations have primarily used randomized controlled trials (RCTs) and other observational settings evaluating daily-life functioning. Researchers examined how symptoms change over time and how often patients experienced acute or disruptive episodes.

The findings describe patterns observed in the cohorts involved. Some trials reported patterns such as how symptoms evolved in the observed populations, including the frequency of vertigo episodes and patient-reported outcomes describing perceived discomfort linked to the condition. Research also examined outcomes related to systemic or functional imbalance and daily functioning or activity level. However, evidence remains limited and heterogeneous, with variations in reported outcomes across the different studies. For example, some research highlights changes measured during the study period, while other evidence only contributes to understanding general symptom patterns.

Evidence for use in Vestibular Vertigo

Studies have explored the use of Vertiserc in patients with vestibular vertigo and other balance disorders, which involve conditions marked by functional limitations and systemic or functional imbalance. Research examined individuals with fluctuating or unstable symptoms, focusing on episodes where symptoms become more noticeable. These investigations included trials and observational studies, typically assessing short-term or episodic symptom patterns.

Findings from these studies describe patterns observed in the measured outcomes related to physical discomfort and the duration of episodic or acute changes. Findings indicate patterns where symptoms appeared to evolve over the defined time intervals observed in the research. However, many reported outcomes were short-term and based on smaller populations. The findings help contextualize how patients reported their experience during the study period.


What Is Still Uncertain about Vertiserc (Betahistine)

Research indicates the primary gaps concerning the characterization of long-term outcomes, as follow-up durations were limited across much of the available evidence base. Long-term effects are not fully established, and this area requires more focused research. Findings indicate data heterogeneity across studies, and consistency in findings is not uniform.

Furthermore, comparative evidence against all other established approaches is often lacking. Sample sizes were modest in many key trials, and results apply only to the specific populations studied. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes, especially where data are still emerging.

Frequently Asked Questions (FAQ)

Common questions about Vertiserc (FAQ)


Q: Is Vertiserc the same as Serc or is there a difference?

A: Vertiserc is one of the many brand names for the active ingredient Betahistine. According to official product information, the medicine Serc also contains Betahistine, meaning they share the same medicinal substance.


Q: Does Vertiserc interact with common pain relievers like ibuprofen?

A: Official regulatory documents list specific categories of medicines that interact with Vertiserc, primarily Histamine H1 antagonists (antihistamines) and Monoamine Oxidase Inhibitors (MAOIs). Common pain relievers like ibuprofen are generally not listed in the official product information as specific interacting medicinal products, though discussions should always be held with a healthcare provider.


Q: How quickly does Vertiserc start working to help with vertigo?

A: Official product information suggests that while some people may experience an initial effect within a few days of starting treatment, it can often take several weeks before the full expected benefit of the medicine is noticed.


Q: Can taking Vertiserc make me feel tired or drowsy?

A: Drowsiness or fatigue is not listed among the most common adverse reactions in regulatory documents. However, some post-marketing reports indicate that this side effect may occur in rare cases.


Q: What are the most commonly reported side effects of Vertiserc?

A: Based on clinical data, the most common adverse reactions reported (occurring in up to 1 in 100 users) are headache, nausea, and dyspepsia (indigestion).


Q: Is Vertiserc a long-term treatment or just for short periods?

A: Regulatory guidance indicates that treatment with this medicine is often characterized as long-term. It is typically continued for several months, with the dose adjusted over time based on the response.


Q: Does Vertiserc work for all types of dizziness or just specific conditions?

A: The medicine is primarily indicated for symptoms related to Ménière's disease and vestibular vertigo. Regulatory text specifies that the medicine is indicated for these conditions, and its use is not recommended for other specific types of dizziness.


Q: Are there any known issues with Vertiserc and blood pressure medication?

A: Official information advises caution and careful monitoring for patients who have pre-existing severe hypotension (very low blood pressure). Specific interactions with commonly prescribed anti-hypertensive medications are not generally listed in the official interaction section, but caution is advised for patients with pre-existing severe hypotension.


Q: How does Vertiserc target the inner ear to reduce vertigo?

A: Vertiserc is thought to have a dual action. It works as an agonist on histamine H1 receptors to help improve blood flow (microcirculation) in the inner ear, and it works as an antagonist on histamine H3 receptors to modulate central vestibular signaling to help promote the reorganization of balance input.


Q: Why is Vertiserc sometimes prescribed for tinnitus (ringing in the ears)?

A: Official documentation lists tinnitus as one of the symptoms of Ménière's disease, which is the condition the medicine is indicated for. The medicine is intended for the symptomatic treatment of the complex of symptoms associated with the condition.


Q: Can Vertiserc affect my ability to drive or operate machinery?

A: Official regulatory documentation states that the medicine itself is considered unlikely to affect the ability to drive or operate machinery. However, the underlying condition being treated, such as Ménière's syndrome, may cause dizziness and sickness, which can affect these abilities.


Q: What happens when you stop taking Vertiserc suddenly?

A: Patients are instructed in the product information not to stop taking the medication without first consulting their healthcare provider. Stopping treatment should be a discussion between the patient and their healthcare provider.


Q: What foods or drinks should be avoided while on Vertiserc?

A: Official regulatory documents indicate that taking the medicine with food intake only slows down the rate of absorption but does not affect the total amount absorbed. No specific foods or non-alcoholic drinks are formally prohibited for co-administration.


Q: Are there generic versions of Vertiserc available?

A: Yes, regulatory databases often list several products containing the generic name Betahistine from various manufacturers. These generic options, based on the active ingredient Betahistine, are listed in drug registries.


Q: Does Vertiserc cause dry mouth or constipation?

A: Dry mouth and constipation are generally not listed among the common or frequently reported side effects of the medicine based on official regulatory data.


Q: Are there specific symptoms that mean I should stop taking Vertiserc and contact a doctor?

A: Official product information emphasizes contacting a healthcare provider immediately if signs of a severe allergic reaction or hypersensitivity are observed. These may include a rash, itching, swelling of the face, neck, or throat, or difficulty breathing.


Q: Does Vertiserc interact with commonly prescribed anti-anxiety medications?

A: Regulatory documents list specific interactions with Histamine H1 antagonists and MAOIs. Interactions with other classes of anti-anxiety medications are generally not explicitly listed in the official interaction section, but all current medications should be discussed with a prescriber.


Q: Why do doctors often prescribe a starting dose and then adjust it?

A: Official product information states that the recommended dosage often begins with an initial starting dose. The dose is then adjusted individually based on the clinical response that is observed over time.


Q: What is the difference between Vertiserc and meclizine (Antivert)?

A: Meclizine (Antivert) is an H1 antagonist (an antihistamine), and official documents note that taking it with Betahistine may lead to a mutual attenuation of effect. Meclizine is also associated with drowsiness, while Betahistine is generally considered less likely to cause this effect.


How should Vertiserc be stored and disposed of?

How to Store and Dispose of Vertiserc (Betahistine)

Official regulatory documents define specific, non-advisory instructions for storing and disposing of this medicine.

Required Storage and Handling

Labeled Storage Temperature Requirements Not above 30 C.
Moisture Protection Requirements Must be stored to protect from moisture.
Packaging Constraints Keep in the original pack; do not transfer to another container.
Child-Safety Requirement Must be kept out of the sight and reach of children.

Official Disposal Instructions

Expired or unused Vertiserc must not be disposed of via wastewater or household waste. Disposal instructions mandate returning the product to a pharmacist to help protect the environment.


This storage profile mandates controlled temperature and protection from moisture by preserving the original packaging, which is directly linked to the product's stability. Disposal must follow pharmaceutical waste guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vertiserc found in:

A-Z Index: